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ABSTRACT
Objectives To examine the management of diabetes
between 2001 and 2007 in the United Kingdom and to
assess whether changes in the quality of care reflect
existing temporal trends or are a direct result of the
implementation of the quality and outcomes framework.
Design Retrospective cohort study.
Setting 147 general practices (annual list size over 1
million) across the UK.
Patients People with type 1 or type 2 diabetes.
Main outcome measures Annual prevalence of diabetes
andattainment of processand clinical outcomesover the
three years before and the three years after the
introduction of the quality and outcomes framework.
Results Significant improvements in process and
intermediate outcome measures were observed during
the six year period, with consecutive annual
improvements observed before the introduction of
incentives. However, the current diagnostic case
definition for the quality and outcomes framework does
notcaptureuptotwothirdsofpeoplewithtype1diabetes
and a third of people with type 2 diabetes. After the
introduction of the quality and outcomes framework,
existing trends of improvement in glycaemic control,
cholesterol levels, and blood pressure were attenuated,
particularly in people with diabetes who did not meet the
case definition of the quality and outcomes framework.
The introduction of the quality and outcomes framework
did not lead to improvement in the management of
patients with type 1 diabetes, nor to a reduction in the
number of patients with type 2 diabetes who had HbA1c
levels greater than 10%. Introduction of the quality and
outcomes framework may have increased the number of
patients with type 2 diabetes with HbA1c levels of ≤7.5%;
odds ratio 1.05 (95% confidence interval 1.01 to 1.09;
P=0.02).
Conclusions The management of people with diabetes
has improved since the late 1990s, but the impact of the
quality and outcomes framework on care is not
straightforward; upper thresholds may need to be
removed or targets made more challenging if people are
to benefit. Many patients in whom care may be
suboptimal may not be captured in the quality and
outcomes framework assessment.
INTRODUCTION
Performance based payment incentives are nowa rou-
tinepartofmanyhealtheconomies.
1In April2004the
quality and outcomes framework was first introduced
as part of the general practitioner contract in the Uni-
tedKingdom.
2Thisschemeoffersfinancialrewardsfor
achieving a series of process outcome measures (what
isactuallydoneingivingandreceivingcare)andinter-
mediate outcome measures (changes in health status
that affect subsequent health outcomes) that should
improve the quality of patient care. The quality and
outcomes framework comprises a range of criteria
grouped into four domains: clinical, organisational,
patient experience, and additional services.
3 For the
period 2006-7 a total of 80 indicators were included
in the clinical domain, with a maximum of 655 points
achievablefromanoveralltotalof1000points.Indica-
tors for diabetes account for 93 of these points, the lar-
gest single clinical area, and cover 18 separate
indicators covering structure (maintaining a register
of patients with diabetes), process (measurement),
and intermediate outcomes such as blood pressure,
cholesterollevel,andglycaemic(HbA1clevel)control.
Payments are staged, and to be eligible for maximum
payment practices are required to achieve a minimum
targetbeforetheyarepaid—thatis,thelowerthreshold
and a maximum or upper threshold.
4 Maximum
thresholds for most clinical process indicators in dia-
betes are currently set at 90% but are lower for inter-
mediateoutcomeindicators.Thustheupperthreshold
fortheproportionofpeoplewithHbA1clevelsof7.5%
or less is 50%, for a blood pressure reading of 145/
85 mm Hg or less is 60%, and for a cholesterol level
of 5 mmol/l or less is 70%.
4 When a general practi-
tioner (or the patient) judges that treatment to these
targetsisinappropriate—forexample,terminaldisease
or patient choice—a patient may be “excepted” from
the indicator denominator.
3 Within the diabetes
domain the median exception reporting rate is 5.4%.
5
Data on people with diabetes are identified for ana-
lysis in the quality and outcomes framework using pri-
mary care morbidity codes (Read codes). Read codes
are a hierarchical coding system used to code clinical
data, including signs, symptoms, procedures,
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6 The current version of
Readcodesare fivecharacterslong,withthe firstchar-
acter indicating the disease area and later characters
providing more precise detail.
7 When the quality and
outcomesframeworkwasfirstintroduced,peoplewith
diabetes were identified on the basis of the presence of
anydiabetesReadcode(C10andanycodesbelowitin
the hierarchy). In April 2006 the case definition for
diabeteswaschangedtoanarrowersetofmorespecific
Read codes; identifying type 1 diabetes mellitus (the
C10E hierarchy: C10E0 to C10EP) and identifying
type2diabetesmellitus(theC10Fhierarchy:C10F0to
C10FQ).
8 Studies have shown that prevalence is
underestimated if only these specific C10E and C10F
Read codes are used, and interpretation of the change
in the quality and outcomes framework indicators has
proved difficult because of this change in case
definition.
89Furthermore, even the use of the less spe-
cific C10 Read codes may exclude some people with
diabetes from evaluation through the quality and out-
comes framework.
Since the introduction of the quality and outcomes
framework a series of studies has suggested an
improvement in the management of people with dia-
betesinprimarycare.
9-12Notably,onestudysuggested
“thattheintroductionofpayforperformancewasasso-
ciated with a modest acceleration in improvement” in
the management of diabetes.
10 However, this work
assessed care at only three time points, one of which
followed the introduction of the quality and outcomes
frameworkand wasbasedonrelatively smallnumbers
of selected patients and therefore may not be fully
representative of care. Other studies have focused on
specific regions in the UK and may not be
generalisable.
1112 It therefore remains unclear to what
extent the introduction of incentives has impacted on
existing temporal trends, reflecting, for example, the
national quality improvement strategy.
10
We examined the prevalence of diabetes and the
proportionofpeoplemeetingtargetsfordiabetesman-
agement annually from April 2002 to March 2007
(three years before and three years after the introduc-
tion of the quality and outcomes framework). We also
assessedtheimpactofthequalityandoutcomesframe-
work on clinical outcomes (glycaemic control, choles-
terol levels, and blood pressure) in people with type 1
and type 2 diabetes.
METHODS
We obtained data from the doctors’ independent net-
work (DIN)-LINK database, which contains anon-
ymised computer records from primary care
practices in the UK using iSOFT (previously
TOREX) clinical systems includingmorbidity coding,
biochemical test results, prescribing data, and
ACORN geodemographic classification (a classifica-
tion of residential neighbourhoods—a deprivation
score).
1314 The age-sex structure of the DIN-LINK
database has been shown to be similar to the UK aver-
age, but practices in the south of England and higher
socioeconomic groups are over-represented.
15 We
identified people with a diagnosis of diabetes from
practices with continuous data over a 10 year period,
from 1 April 1997 to 31 March 2007. Analyses were
done using SAS V9.1.
Identification of people with diabetes
We identified people with diabetes if they had a Read
code for diabetes or one or more prescriptions for oral
antidiabeticdrugs,insulin,orglucosetestingkits.MJC
and AS identified relevant Read codes, which were
verified by a clinician (RJM). Read codes included
those in the C10 hierarchy and other diabetes related
Read codes including diabetes monitoring, referrals,
and diabetes related eye and foot complications. We
excluded women with gestational diabetes unrelated
to pre-existing diabetes. People were classified as hav-
ing type 1 diabetes if they were prescribed insulin (or
an insulin device), did not have a Read code for type 2
diabetes, or had any previous prescription for an oral
antidiabetic drug. The remaining people were classi-
fied as having type 2 diabetes.
In addition, in order to be able to interpret the effect
ofthechangeindiagnosticcasedefinitioninthequality
and outcomes framework which occurred from April
2006, we also identified the first occurrence of Read
codes in the C10E (type 1 diabetes mellitus) or C10F
(type2diabetesmellitus)hierarchiesforpeopleduring
the study period.
8
Prevalence of diabetes
The prevalence of diabetes was estimated annually on
the 31 March from 2002-7. We considered all people
with a diagnosis of diabetes who were registered in
each practice on each date.
Attainment of targets in quality and outcomes framework
We carried out analyses on attainment of diabetes and
smoking outcomes using data between 1 January 2001
and31March2007,asannualtargetsinthequalityand
outcomes framework are assessed over a 15 month
period (Department of Health business rules).
16
These definitions were adhered to with the following
exceptions: for our principal analyses we considered
all people with diabetes (rather than only those with
clinical Read codes). In the primary analyses we
excludeddiabetesexceptionreportingcodes(9h4hier-
archy) that did not give the reason for exception. We
did, however, include outcome specific exception
codes such as contraindication codes and maximal
therapy codes. We undertook a series of sensitivity
analyses to assess attainment of outcomes in people
with recorded Read codes in the C10E and C10F hier-
archies and the impact of diabetes exception reporting
(9h4 codes) on glycaemic control.
Impact of quality and outcomes framework on glycaemic
control
Weassessedtherelationbetweenattainmentofglycae-
mictargets(HbA1clevels≤7.5%and≤10%)andyearof
assessment, the introduction of the quality and
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nostic coding definitions, using mixed models with a
logit link and binomial error and a random effect term
describing the effect of practice with a Gaussian error
structure using the SAS nlmixed procedure (SAS V9.
1). Four separate models were produced: response
variable HbA1c level ≤7.5% in people with type 1 dia-
betes; response variable HbA1c level ≤10% in people
with type 1 diabetes; response variable HbA1c level
≤7.5% in people with type 2 diabetes; response vari-
able HbA1c level ≤10% in people with type 2 diabetes.
ForpatientswithmultipleassessmentsofHbA1clevels
recorded during each year we used the latest assess-
ment before the quality and outcomes framework
referencedate.Weassessedlinearandnon-linearfunc-
tional forms (natural logarithm and exponential func-
tions)foryear.Toallowforasuddenshiftintherateof
changeasaresultoftheintroductionofthequalityand
outcomesframeworkinadditiontoannualchangeswe
used an additional variable to indicate whether the
qualityandoutcomesframeworkwasbeingimplemen-
ted.Thepresenceofthenewqualityandoutcomesfra-
meworkdiagnosticcoding(C10EorC10Fhierarchies)
were also coded variablesto assessthe impact of being
included in the pay for performance review on glycae-
mic control. Interaction terms were assessed. We
derived the denominator degrees of freedom from
the number of practices. Akaike’s information criter-
ion was used to determine the best model fit and most
appropriate functional form for annual changes.
17
RESULTS
Overall, 147 of the 300 practices contributing to the
DIN-LINK database had usable data over the study
period, of which 34 (23%) provided pharmacy dispen-
sing services in addition to primary medical care. The
practices employed a mean number of 5.8 general
practitioners (SD 2.9) and on 31 March 2007 had a
mean list size of 8929 (SD 4147).
Prevalence of diabetes
During the six years of the study period (2002-7) the
recordedprevalenceoftype1diabetesremainedstable
whereas the recorded prevalence of type 2 diabetes
increased (fig 1). The use of specific morbidity codes
for type 1 and type 2 diabetes increased over time but
remained about two thirds of the total codes for dia-
betes at the end of the study period.
Changes in quality and outcomes framework indicators
over time
Improvementsinalldiabetesindicatorswereobserved
over the study period (tables 1 and 2 and fig 2). The
proportion of people with type 1 diabetes attaining
process targets was greater than 70% in 2007, with
the exception of testing for microalbuminuria. The
proportion of people with type 2 diabetes attaining
these targets was higher.
Theproportionofpeopleattainingintermediateout-
comesalsoimprovedovertimebutwaslowerthanthat
observedforprocesstargets.Theproportionofpeople
with type 1 and type 2 diabetes attaining targets for
glycaemic control (HbA1c level ≤7.5% and ≤10%),
cholesterol level, and blood pressure showed attenua-
tion of annual trends in improvement after the intro-
duction ofthe quality and outcomesframework(fig 2).
This effect appeared greater for the proportion of peo-
ple attaining glycaemic control.
Model results (table 3) showed significant annual
increases in the proportion of people attaining targets
for HbA1c levels. Target attainment was significantly
higher in those people with a quality and outcomes
framework diagnostic Read code (with the exception
ofpeoplewithtype1diabetesandHbA1ctarget≤10%).
Introduction of the quality and outcomes framework
was only significantly associated with an increase in
the proportion of people attaining HbA1c target
≤7.5% in people with type 2 diabetes, and this effect
was relatively small.
Characterisation of people without quality and outcomes
framework case definition Read codes
In light of the findings, the use of the quality and out-
comes framework diagnostic Read codes was exam-
ined in the most recent (2007) cohort. A total of 3811
peoplewithtype1diabeteswereinthe2007cohortfor
HbA1c levels, of whom 1228 had a specific C10E code
andwouldbeassessedinthequalityandoutcomesfra-
mework. Of the remaining 2583 people, none had a
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Fig 1 | Prevalence of type 1 and type 2 diabetes across study
period
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scription for insulin but no oral antidiabetic drug
before the quality and outcomes framework reference
date.Exploratoryanalysesindicatedthatpeoplewitha
C10E hierarchy Read code were younger than those
without a C10E code (mean ages 40.6 v 50.4 years;
P<0.001). They were also more likely to be men
(61.4% v 55.3%, P<0.001).
A total of 42032 people with type 2 diabetes in the
2007cohortforHbA1clevelswereidentified,ofwhom
29674 had a specific C10F hierarchy Read code. Of
the remaining 12358 people without a C10F code,
8994 (72.8%) had either a prescription for an oral
agentandinsulinorinsulindevicebeforethereference
date or a Read code indicating diabetic treatment.
Overall, 2460 people (19.9%) had either the broader
diabetes Read codes (C10 hierarchy) or the Read
codes indicating screening for, or complications asso-
ciated with, diabetes, such as eye and foot complica-
tions. Of the remaining people, 904 (7.3%) had Read
codesindicatingassessmentorcareofdiabetes.People
with a C10F code were older than those without a
C10F code (mean ages 66.1 v 63.5 years; P<0.001).
They were also more likely to be men (55.2% v
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Fig 2 | Proportion of patients with diabetes meeting quality and outcomes framework targets for HbA1c level, cholesterol level,
and blood pressure. For patients with multiple assessments during each period the last measurement during the year was
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Variables 2002 2003 2004 2005 2006 2007
DM2 with record of body
mass index
1201/4028 (29.8) 1448/4074 (35.5) 2143/4086 (52.5) 3104/4042 (76.8) 3301/4117 (80.2) 3338/4146 (80.5)
DM3 with record of
smoking status except
never smokers, when
smoking status should be
recorded once
2571/4028 (63.8) 2763/4074 (67.8) 3197/4086 (78.2) 3687/4042 (91.2) 3737/4117 (90.8) 3827/4146 (92.3)
DM4 smokers with record
that advice on smoking
cessationhasbeenoffered
218/885 (24.6) 232/898 (25.8) 482/938 (51.4) 744/892 (83.4) 764/929 (82.3) 780/902 (86.5)
DM5withrecordofHbA1cor
equivalent
2337/4028 (58.0) 2589/4074 (63.6) 3050/4086 (74.7) 3433/4042 (84.9) 3534/4117 (85.8) 3540/4146 (85.4)
DM5withrecordofHbA1cor
equivalent (using diabetes
exception reporting)
2337/4028 (58.0) 2589/4074 (63.6) 3036/4068 (74.6) 3249/3732 (87.1) 3168/3607 (87.8) 3220/3661 (88.0)
DM20 with last recorded
HbA1c (or equivalent) level
of ≤7.5%*
613/3799 (16.1) 657/3858 (17.0) 793/3873 (20.5) 907/3639 (24.9) 912/3723 (24.5) 1003/3811 (26.3)
DM20withC10Ecodesand
last recorded HbA1c (or
equivalent)levelof≤7.5%*
53/289 (18.3) 83/394 (21.1) 146/587 (24.9) 221/782 (28.3) 262/1013 (25.9) 349/1228 (28.4)
DM7 with last recorded
HbA1c (or equivalent) level
of ≤10%
1861/3799 (49.0) 2076/3858 (53.8) 2462/3873 (63.6) 2658/3639 (73.0) 2737/3723 (73.5) 2805/3811 (73.6)
DM7 with C10E codes and
last recorded HbA1c (or
equivalent) level of ≤10
123/289 (42.6) 192/394 (48.7) 364/587 (62.0) 577/782 (73.8) 712/1013 (70.3) 901/1228 (73.4)
DM21withrecordofretinal
screening†
1113/4028 (27.6) 1350/4074 (33.1) 2150/4086 (52.6) 2939/4026 (73.0) 3038/4062 (74.8) 3186/4015 (79.4)
DM9 with record of
presence or absence of
peripheral pulses
339/4028 (8.4) 461/4074 (11.3) 1150/4084 (28.2) 2726/4024 (67.7) 2986/4082 (73.2) 2955/4100 (72.1)
DM10 with record of
neuropathy testing
207/4028 (5.1) 318/4074 (7.8) 1002/4084 (24.5) 2677/4024 (66.5) 2967/4082 (72.7) 2945/4100 (71.8)
DM11 with record of blood
pressure reading
2763/4028 (68.6) 3013/4074 (74.0) 3285/4086 (80.4) 3644/4042 (90.2) 3721/4117 (90.4) 3759/4143 (90.7)
DM12 with last recorded
blood pressure of ≤145/
85 mm Hg
1684/3799 (44.3) 1921/3858 (49.8) 2173/3887 (55.9) 2558/3794 (67.4) 2726/3850 (70.8) 2810/3893 (72.2)
DM13 with record of
microalbuminuria testing
440/3934 (11.2) 600/3979 (15.1) 1053/3978 (26.5) 2202/3878 (56.8) 2450/3929 (62.4) 2553/3955 (64.6)
DM22 with record of
estimated glomerular
filtration rate or serum
creatinine testing‡
1839/4028 (45.7) 2103/4074 (51.6) 2595/4086 (63.5) 3208/4042 (79.4) 3386/4117 (82.2) 3433/4146 (82.8)
DM15 with diagnosis of
proteinuria or
microalbuminuria and
treated with ACE inhibitors
(or A2 antagonists)
80/108 (74.1) 80/113 (70.8) 94/136 (69.1) 186/245 (75.9) 224/286 (78.3) 248/305 (81.3)
DM16 with record of total
cholesterol level
1998/4028 (49.6) 2235/4074 (54.9) 2678/4086 (65.5) 3221/4042 (79.7) 3343/4117 (81.2) 3364/4146 (81.1)
DM17 with last measured
total cholesterol level of
≤5mmol/l
989/3798 (26.0) 1215/3847 (31.6) 1581/3867 (40.9) 2069/3722 (55.6) 2262/3763 (60.1) 2370/3795 (62.5)
DM18 vaccinated against
influenza in preceding 1
September to 31 March
2032/3986 (51.0) 1969/4030 (48.9) 2138/3950 (54.1) 2413/3475 (69.4) 2617/3585 (73.0) 2660/3637 (73.1)
DM identifies specific quality and outcomes framework diabetes indicator.
ACE=angiotensin converting enzyme.
*Formerly DM6 and used HbA1c target of 7.4%.
†Formerly DM8 and changed as practices need to show that patients have received screening.
‡Formerly DM14 and included record of only serum creatinine level.
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nomic class (66.8% v 58.3%; P<0.001).
DISCUSSION
Significant improvements were seen in all of the qual-
ity and outcomes framework clinical indicators over
time for diabetes care in the UK. The results also high-
light differences in the management of people with
type1andtype2diabetes,asthosewithtype2diabetes
generally underwent more testing for diabetes related
complications than people with type 1 diabetes. This
mightreflectthefactthatahigherproportionofpeople
withtype1diabetesreceivespecialistcarethatmaynot
be as well recorded in primary care records.
18 By the
end of the study in 2007, attainment of process mea-
sures was high. Whether this was a direct result of the
quality and outcomes framework or reflects existing
trends in improvement of care over time in response
to clinical evidence, national guidelines, and other
driving factors remains unclear.
10
Significant improvements in clinical intermediate
outcome measures (glycaemic control, cholesterol
level, and blood pressure) were observed over the
study period, with successive improvements being
observed before the introduction of the quality and
outcomes framework. This could in part be due to
awareness among general practitioners of its impend-
ing introduction or the influence of national service
frameworks in England and Wales and other clinical
governance initiatives. After the introduction of the
quality and outcomes framework, the trends appear
to be attenuated. One study observed a modest accel-
eration in the improvement of care between 2003 and
2005 compared with 1998 to 2003, which the authors
suggested might have been associated with the intro-
duction of pay for performance.
10 In our study, out-
comes appeared to improve consistently between
2002and 2005, withattenuationin observedimprove-
ment between 2005 and 2007. This attenuation could
reflect the increasing difficulty of target attainment in
poorlycontrolledpeoplebecauseeveninconditionsof
a clinical trial some people are unable to attain long
term control.
19 However the attenuation of temporal
trends might also reflect the lack of further incentive
after attainment of the upper payment thresholds (the
ceilingeffect).Thiscouldsuggestthatupperthresholds
need to be removed or targets made more challenging
in line with the evidence base rather than the current
alignment with lower audit targets. Both the lower and
the upper thresholds were, however, shifted upwards
forseveralintermediateoutcomesin2006,whichdoes
not appear to be reflected in subsequent target attain-
ment, suggesting that further changes would require
careful evaluation. If the observed ceiling effect does
represent the natural equilibrium of current optimal
management in primary care, this highlights the
remaininggapintreatmentandtheneedfornewthera-
pies, improved education, or management strategies.
In2007themonitoringandcontrolofglycaemiastill
seemed suboptimal in some people, with over 10% of
people having no record of an HbA1c level or
equivalent in the previous 15 months. Twenty six per
centofpeoplewithtype1diabetesand17%withtype2
diabetes had an HbA1c level of more than 10%, and
41% of people with type 2 diabetes and 74% with
type 1 diabetes had an HbA1c level of more than
7.5%.Similarly,nearlyathirdofpatientshadevidence
of raised blood pressure and over a quarter of patients
had raised serum cholesterol levels. The introduction
of the quality and outcomes framework seems to be
significantly associated with better glycaemic control
in people with type 2 diabetes for the more stringent
target (HbA1c level ≤7.5%), although the quality and
outcomesframeworkdidnotseemtosignificantlypre-
dict attainment of the higher target (HbA1c level
≤10%), and attenuation in trends was observed for
both targets. Since the maximum payment threshold
for payment for an HbA1c target of 7.5% or less is
50%, the quality and outcomes framework seems to
offer no further incentive for optimal glycaemic con-
trol for many people. However, since attainment was
over 60% on average, perhaps greater thought is
needed for additional targeting of poorly performing
practices as opposedto general interventions or devel-
oping and implementing more nuanced indicators. It
may be, for example, that introducing a system of
tightly linked process measures into the diabetes
domain, similar to the system used by the Veterans
Administration,
20 could improve care further,
although this would require some modification to the
information technology infrastructure underpinning
the quality and outcomes framework.
Weobservedsubstantialvariationinthelevelofgly-
caemic control attained across practices. For example,
the median proportion of people with type 1 diabetes
achieving the HbA1c target of 7.5% or less in 2007 was
25.8% (interquartile range 20.0-32.5%), with one prac-
tice reporting that all patients had HbA1c levels less
than or equal to 7.5% and for people with type 2 dia-
betes the median was 60.1% (55.4-65.5%), with 14
practices reporting that less than half of patients
achieved the target and only three practices reporting
thatover threequartersofpatientsachievedthe target.
Characteristics of the patient population in each prac-
tice, including prevalence of disease, case mix, and list
size have been shown to influence attainment of
targets.
2122 Management may also be affected by the
views of patients and healthcare providers.
23
Subgroup analyses of attainment of intermediate
outcomes (glycaemic control, cholesterol level, and
blood pressure) by patients with or without a Read
code meeting the quality and outcomes framework
case definition (C10E and C10F) indicate that people
included in the quality and outcomes framework
denominator, and particularly those with type 2 dia-
betes, were in general more likely to attain the targets.
Our finding that older people, men, and those from
affluent backgrounds seem more likely to have a spe-
cific C10F hierarchy code and therefore be assessed
within the quality and outcomes framework is consis-
tentwithothers’workontherelationbetweenpatients’
personal characteristics and attainment of targets, and
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Variables 2002 2003 2004 2005 2006 2007
DM2 with record of body
mass index
12 810/28 451 (45.0) 16 559/32 037 (51.7) 24 093/35 599 (67.7) 33 131/39 175 (84.6) 36 824/42 816 (86.0) 40 153/46 189 (86.9)
DM3 withrecord ofsmoking
status except never
smokers, where smoking
status should be recorded
once
20 640/28 451 (72.6) 24 535/32 037 (76.6) 30 320/35 599 (85.2) 37 107/39 175 (94.7) 40 327/42 816 (94.2) 43 824/46 189 (94.9)
DM4 smokers with record
that advice on smoking
cessation has been offered
1274/4629 (27.5) 1793/5196 (34.5) 3336/5620 (59.4) 5243/5978 (87.7) 5467/6317 (86.5) 6115/6878 (88.9)
DM5 withrecordofHbA1cor
equivalent level
20 573/28 451 (72.3) 24 554/32 037 (76.6) 29 750/35 599 (83.6) 34 627/39 175 (88.4) 37 752/42 816 (88.2) 40 311/46 189 (87.3)
DM5 with record of HbA1c
level or equivalent (using
diabetes exception
reporting)
20 573/28 451 (72.3) 24 553/32 035 (76.6) 29 658/35 465 (83.6) 33 176/37 197 (89.2) 35 615/39 906 (89.3) 38 116/43 172 (88.3)
DM20 with last recorded
HbA1c(orequivalent)levelof
≤7.5%*
10 292/26 082 (39.5) 12 997/29 413 (44.2) 16 193/32 658 (49.6) 19 756/35 271 (56.0) 22 043/38 621 (57.1) 24 940/42 032 (59.3)
DM20 with C10F codes and
last recorded HbA1c (or
equivalent) level of ≤7.5%*
3841/8103 (47.4) 5879/11 198 (52.5) 8858/15 250 (58.1) 12 750/19 698 (64.7) 15 979/24 448 (65.4) 20 068/29 674 (67.6)
DM7 with last recorded
HbA1c(orequivalent)levelof
≤10%
17 327/26 082 (66.4) 20 933/29 413 (71.2) 25 562/32 658 (78.3) 29 412/35 271 (83.4) 32 191/38 621 (83.4) 34 756/42 032 (82.7)
DM7 with C10F codes and
last recorded HbA1c (or
equivalent) level of ≤10%
5779/8103 (71.3) 8652/11 198 (77.3) 13 074/15 250 (85.7) 17 950/19 698 (91.1) 22 332/24 448 (91.3) 27 090/29 674 (91.3)
DM21 with record of retinal
screening†
11 523/28 451 (40.5) 14 976/32 037 (46.8) 21 131/35 595 (59.4) 28 985/39 004 (74.3) 31 804/42 429 (75.0) 35 608/45 265 (78.7)
DM9withrecordofpresence
or absence of peripheral
pulses†
5197/28 451 (18.3) 7195/32 037 (22.5) 14 626/35 594 (41.1) 29 613/39 059 (75.8) 34 144/42 554 (80.2) 36 556/45 807 (79.8)
DM10 with record of
neuropathy testing
3474/28 451 (12.2) 5282/32 037 (16.5) 12 954/35 594 (36.4) 29 419/39 059 (75.3) 34 031/42 554 (80.0) 36 339/45 807 (79.3)
DM11 with record of blood
pressure reading
24 287/28 451 (85.4) 28 334/32 037 (88.4) 32 337/35 599 (90.8) 37 037/39 174 (94.5) 40 475/42 810 (94.6) 43 566/46 146 (94.4)
DM12 with last recorded
blood pressure of ≤145/
85 mm Hg
11 557/26 081 (44.3) 14 481/29 413 (49.2) 17 846/32 661 (54.6) 23 020/35 457 (64.9) 26 203/38 759 (67.6) 29 764/42 110 (70.7)
DM13 with record of
microalbuminuria testing
4186/28 107 (14.9) 7447/31 658 (23.5) 12 715/35 072 (36.3) 25 686/38 053 (67.5) 30 540/41 210 (74.1) 33 291/44 234 (75.3)
DM22 with record of
estimated glomerular
filtration rate or serum
creatinine testing‡
18 053/28 451 (63.5) 22 225/32 037 (69.4) 28 374/35 599 (79.7) 35 414/39 175 (90.4) 39 124/42 816 (91.4) 42 181/46 189 (91.3)
DM15 with diagnosis of
proteinuria or
microalbuminuria and
treated with ACE inhibitors
(or A2 antagonists)
266/429 (62.0) 356/507 (70.2) 623/821 (75.9) 1942/2360 (82.3) 2272/3329 (83.3) 3480/4026 (86.4)
DM16 with record of total
cholesterol level
19 298/28 451 (67.8) 23 438/32 037 (73.2) 28 821/35 599 (81.0) 34 832/39 175 (88.9) 38 392/42 816 (89.7) 41 431/46 189 (89.7)
DM17 with last measured
total cholesterol level of
≤5 mmol/l
8761/26 071 (33.6) 12 213/29 275 (41.7) 16 984/32 261 (52.7) 23 055/34 562 (66.7) 26 823/37 704 (71.1) 30 305/40 860 (74.2)
DM18 vaccinated against
influenza in preceding 1
September to 31 March
17 527/27 888 (62.9) 19 458/31 341 (62.1) 23 427/33 952 (69.0) 28 260/34 435 (82.1) 31 435/37 978 (82.8) 34 189/40 897 (83.6)
DM identifies specific quality and outcomes framework diabetes indicator.
ACE=angiotensin converting enzyme.
*Formerly DM6 and used target HbA1c of 7.4%.
†Formerly DM8 and changed as practices need to show that patients have received screening.
‡Formerly DM14 and included record of only serum creatinine level.
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work may not have been as efficient in reducing
inequalities in health in diabetes as was hoped.
2224
Detailed assessment of Read codes and prescriptions
forpatientsthatdidnotmeetthecurrentcasedefinition
for the quality and outcomes framework indicates that
an important group of people that seem to have dia-
betesarenolongerincludedwithinthequalityandout-
comes framework. Some of these (<7%) may purely
have been included in the study definition on the
basis of monitoring for suspected diabetes and there-
fore reasonably not received comprehensive diabetes
care, which may contribute to the apparent reduced
care in people not meeting the diagnostic case defini-
tion of the quality and outcomes framework. An alter-
native explanation for the apparent reduced level of
care in people without C10F codes is the selective
exclusion of poorly managed patients by clinicians
that might lead to increased income. However such
“gaming” was not seen on a wide scale in a recent eva-
luation of exception reporting in the quality and out-
comes framework.
5
Our results indicate that identification of patients
using the diagnostic case definition for the quality and
outcomesframework(C10EandC10FhierarchyRead
codes)artificiallydecreasestheobservedprevalenceof
diabetes, as observed by others.
9 Although standar-
disedcodinghasincreasedovertime,weobservedsub-
stantial variation in the use of Read codes across
practices.Forexample,in2007themedianproportion
of people within a practice with type 2 diabetes who
had a C10F code was 72.1% (interquartile range 67.1-
79.3%). Only three practices had over 90% of people
meeting the type 2 case definition of the quality and
outcomes framework and four practices had less than
20% of people defined in this manner. In 2007 nearly
two thirds of people with type 1 diabetes and a third of
people with type 2 diabetes would not be identified
using the diagnostic case definition in the quality and
outcomesframework.Otherstudieshavealsoreported
similar underestimates of prevalence when only
specific diabetes codes are considered.
9 Further stan-
dardisation of coding is required if quality of care is
to be monitored in an unbiased and effective way.
6
This may require widespread education within pri-
mary care before the introduction of new indicators.
Strengths and limitations of the study
Themeanprevalenceinourstudybasedonthequality
and outcomes framework case definition (2.7%, range
0.2-5.1%) was lower than reported nationally by
Department of Health systems (3.7%, range 0.0-
14.4%),
25 although over 90% of practices included in
thequalityandoutcomesframeworkreportedapreva-
lence within our observed range. This may in part
reflect the under-representation of practices in
deprivedareas,which tendto have higherproportions
of people from ethnic minority groups and hence dia-
betes, in the database used in this study.
26-28 The prac-
tices included in the (DIN)-LINK database have a
similar age-sex structure to that of the UK population
buthavebeenshowntoover-representpracticesinthe
south of England and higher socioeconomic groups.
15
In addition the practices included in this study (just
under 50% of those contributing to the DIN-LINK
database) were selected because they had high quality
data available over a 10 year period, which allowed us
to identify and assess the management of patients over
time. These selected practices were spread throughout
GreatBritainbutincludedarelativelyhighproportion
of dispensing practices. We may anticipate that such
practices with capture of higher quality data provide
a different level of care, possibly higher, than those
that do not meet such criteria. Furthermore, ease of
accessibility to dispensing services may mean that
some patients seen in our practices might have
increased uptake and possibly compliance with ther-
apy.
The prevalence of type 1 diabetes may be viewed as
decreasing marginally over time, which could result
from more accurate coding in general practitioners’
notes, particularly in the case of people with type 2
Table 3 |Relation between glycaemic control with time, introduction of quality and outcomes framework, and meeting
diagnostic case definition of quality and outcomes framework
Variables
HbA
1c target ≤7.5% HbA
1c target ≤10%
Odds ratio (95% CI) P value Odds ratio (95% CI) P value
Type 1 diabetes:
Year 1.02 (1.01 to 1.04)† 0.003 1.06 (1.03 to 1.08) <0.001
Quality and outcomes framework * * * *
Presence of C10E Read code 1.41 (1.24 to 1.59) <0.001 0.72 (0.64 to 0.80) <0.001
YearandpresenceofC10EReadcode 0.97 (0.90 to 1.0)† 0.04 * *
Type 2 diabetes:
Year 1.06 (1.05 to 1.08) <0.001 +2.51 (2.13 to 2.95) 0.001
Quality and outcomes framework 1.05 (1.01 to 1.09) 0.02 * *
Presence of C10F Read code 1.67 (1.64 to 1.71) <0.001 1.68 (1.61 to 1.75) <0.001
Years were coded in model as −3 to 2 to indicate their relation to introduction of quality and outcomes framework unless otherwise stated.
*Variable not included in final model as non-significant (P>0.05).
†Year with an exponential transformation.
+Year with log transformation (rescaled years as 1 to 6). Although this rescaled log transformed model had best model fit as judged by Akaike’s
information criterion, this metric is difficult to interpret practically.
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coded as such.
Our sensitivity analyses on patients who had C10E
and C10F Read codes and met the current case defini-
tionforthequalityandoutcomesframeworkwasbased
on identification of these Read codes in the study per-
iod. Some people with earlier recorded morbidity
Read codes may have been missed, but it is standard
practicetoincludeaReadcodeintheelectronicrecord
each time a patient is seen. Although the inclusion of
people without C10 or the more specific C10E and
C10F codes in the analysis might be criticised, other
Read codes were more commonly in use in the period
before April 2006. Other studies have also used codes
such as the diabetes care codes (66A) and prescription
information to identify patient cohorts
29 and have
noted the inconsistent use of diabetes specific Read
codes.
6 As we aimed to assess the management of peo-
ple with diabetes over time and the impact of the qual-
ityandoutcomesframework,itwasimportanttoavoid
spurioustrendsasaresultofchangesindiagnosticcase
definition.
9 We also included people with codes for
exception reporting (9h4 codes) as these codes were
not in use before April 2005 and so their use would
have led to an inaccurate assessment of change in
careover thestudyperiod.Amoreinclusiveapproach
considering the entire population of people with dia-
betesprovidesaclearerpictureofcarebothbeforeand
after the implementation of the quality and outcomes
framework.
Conclusions
The management of people with diabetes in the UK
has improved since the late 1990s. The relation
between incentives and attainment of targets may
not, however, be as straightforward as initial reports
suggest. Pay for performance may have contributed
to the improvement in diabetes care but the relative
importance of the quality and outcomes framework
to other national quality improvement strategies is
unclear. Our work and that of others highlights the
potential unintended consequences of the scheme,
which include selective inclusion of patients in the
scheme through the removal
30 or addition of Read
codes, exclusion of patients through exception
reporting,
22 and potential threshold effects, all of
which require further evaluation. The scheme in its
presentformfailstocapturealmostonethirdofpeople
inwhomcaremaybesuboptimalandmayevenleadto
reduced levels of care for some groups of patients.
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